Abstract
Based on recent success of intra-articular (IA) Botulinum neurotoxin type A (BoNT/A; OnabotulinumtoxinA) in patients with osteoarthritis, we examined if repeat IA-BoNT/A is an effective antinociceptive in patients with refractory arthroplasty pain. 11 patients with refractory chronic arthroplasty joint pain without any evidence of infection or prosthesis loosening were referred by orthopedic surgeons. After discussion of off-label use, each patient underwent IA injection of BoNT/A, repeated based on return of pain on numeric rating scale (NRS) and functional limitation on composite validated scales, Western Ontario McMaster Osteoarthritis index (WOMAC) or Shoulder Pain and Disability (SPADI). 11 patients (10 men, 1 woman) with 14 painful arthroplasty joints (3 bilateral; 12 knee and 2 shoulder) underwent ≥1 IA-BoNT/A injections (8 joints injected once, one joint injected twice only, five joints injected thrice) with doses ranging 100-300 units. Mean age was 68 years (standard deviation, 12) and follow-up ranged 1-28 months. Clinically meaningful reduction of 2-units in pain severity and really meaningful reduction in pain severity (50% reduction) were reported by 6/11 patients (6/13 joints) and 3/11 patients (3/13 joints), respectively, 1 month after the first IA-BoNT/A (100-units each). Significant improvements were noted in composite functional scales (WOMAC/SPADI). Pain relief was sustained at 3-4 month follow-up and was reproducible in those who received repeat injections. No significant adverse events were seen in any patients. A single intra-articular injection of BoNT/A improved pain and function in patients with chronic, refractory painful knee or shoulder arthroplasty, which sustained with repeat injections. Patients who were refractory to the first injection, did not respond to subsequent injections of higher dose of IA-BoNT/A.
Highlights
Total knee arthroplasty (TKA) is the commonest of all total Joint arthroplasty (TJA), with an annual volume of 300,000 in the U.S in 2005 which is projected to increase 6-fold to 3.48 million/year by 2030 [1]
Singh reported by 6/11 patients (6/13 joints) and 3/11 patients (3/13 joints), respectively, 1 month after the first IA-Botulinum neurotoxin type A (BoNT/A) (100-units each)
Significant improvements were noted in composite functional scales (WOMAC/Shoulder Pain and Disability (SPADI))
Summary
Total knee arthroplasty (TKA) is the commonest of all total Joint arthroplasty (TJA), with an annual volume of 300,000 in the U.S in 2005 which is projected to increase 6-fold to 3.48 million/year by 2030 [1]. Botulinum neurotoxin type A (BoNT/A) is a neurotoxin approved for the treatment of several conditions including wrinkles, cervical dystonia etc. It can modulate the release of neuropeptides such as Substance P (SP) and calcitonin gene-related protein (CGRP) and inhibit neurogenic inflammation, [3] which likely underlies its independent antinociceptive effect. Long-term efficacy of IA-BoNT/A for painful TJA is not known, and it is not known if repeat injections are effective. We aimed to examine the long-term effects of IA-BoNT/A (OnabotulinumtoxinA) in patients with chronically painful TJA and the efficacy of repeat IA-BoNT/A injections in these patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
